Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new study finds that inherited genetic variation plays a role in who is likely to benefit from cancer immunotherapies.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
About a quarter of patients with advanced skin cancer experienced tumor shrinkage in a clinical trial.
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
Study offers assurance that the benefits of the combination can be achieved without diminishing patients’ quality of life.
Having diabetes can put a person at greater risk for certain cancers and affect cancer treatment.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
Studies ask whether cancer treatment, such as chemotherapy and immunotherapy, can lead to more severe COVID-19.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
The checkpoint inhibitor is approved for adults and children with relapsed lymphoma.
The immunotherapy combo improved overall survival compared with chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.